Proteosome influenza vaccine

Details Proteosome influenza vaccine Proteosome influenza vaccine

2008-07-15

2008-07-15

Campell, Bruce (Department: 1648)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

Separation or purification

C424S204100, C424S206100, C424S234100, C424S249100, C435S069100

Reexamination Certificate

active

07399840

ABSTRACT:
Improved forms of vaccines which comprise proteosomes and protein antigens are described. Vaccines which contain influenza HA as the antigen are used for illustration as to demonstrate efficacy. Improvements in the preparation of the vaccines themselves and the proteosome component are also included.

REFERENCES:
patent: 4707543 (1987-11-01), Zollinger et al.
patent: 5716637 (1998-02-01), Anselem et al.
patent: 5726292 (1998-03-01), Lowell
patent: 5961970 (1999-10-01), Lowell et al.
patent: 5985284 (1999-11-01), Lowell
patent: 6476201 (2002-11-01), Lowell et al.
patent: WO95/11700 (1995-05-01), None
patent: WO97/10844 (1997-03-01), None
patent: WO98/01558 (1998-01-01), None
Crowe et al. Vaccine, 2006, vol. 24, p. 452-456.
Fynan et al. International Journal of Immunopharmacology, 1995, vol. 17, p. 79-83.
Levi et al. vaccine , 1995, vol. 13, p. 1353-1359.
Jahn-Schmidt, Beatrice, et al. “Toward selective elicitation of TH1-controlled responses: vaccine applications of bacterial surface layer proteins”,Journal of Biotechnology(1996) 44:225-231.
Barchfield. et al.Vaccine(1999) 17:695-704.
Benyedidia, et al.Letters in Peptide Science(1998) 5(5-6):341-344.
Berstad, et al.Vaccine(2000) 18:1910-1919.
Dalseg, R., et al.Vaccines(1999) 17:2336-2345.
Gluck. et al.J. Infect. Dis.(2000) 181:1129-1132.
Hashigucci. et al.Vaccino(1996) 14.113-119.
Levi, R., et al.Vaccine(1995) 13:1353-1358.
Lowell, G.H., et al.J. Exp. Med(1998) 167:658-663.
Lowell, G.H., et al.Science(1955) 240:800-802.
Lowell, G.H., et al. in:New Generation Vaccines. 2nd ed.. Marcel Dekker, Inc. New York, Basil, Hong Kong (1997) pp. 193-206.
Lynch, E.C., et al.Biophys. J.(1984) 45:104-107.
McGhee, et al.J. Immunol.(2000) 165:4778-4782.
Plante, et al.Abstracts of the General Meeting of the American Society for Microbiology.(2000) 100:297.
Slavik, et al. Database accession No. 131•57769, XP002174983 (1998).
Slavik, et al.Acta Virologica(1993) 37(6):449-458.
Tamura, et al.J. Immunol.(1992) 149:981-988.
Lowell, G.H. in:New Generation Vaccines, G.C. Woodrow and M.M. Levine eds., Marcel Dekker, Inc., New York, (1990), p. 141-160; 325-348.
Lowell, et al.Journal of cell biochem(1995) S19A.
Lowell, et al.American Soc for microbio, 2nd Nat Conf.(1995) p. 81.
Lowell, et al.Infec.&Imm(1996) 64(5):1706-1713.
Lowall, et al,Intec.&Imm.(1996) 64(11):4686-93.
Lowell, et al,Journal of Infectious diseases(1997) 175(2):292-301.
Mallett, C.P., et al.Infect. Immun.(1995) 63:2382-2388.
Orr, N., et al.Infect. Immun.(1993) 61:2390.
Wetzler et al., “Gonococcal Porin Vaccine Evaluation: Comparison of Por Proteosomes, Liposomes, and Blebs Isolated from rmp Deletion Mutants,”Journal of Infectious Diseases 166(3):551-555, Sep. 1992.
Wetzler et al., “Characterization and Specificity of Antibodies to Protein I ofNeisseria gonorrhoeaeProduced by Injection with Various Protein I-Adjuvant Preparations,”Journal of Experimental Medicine 168(5):1883-1897, Nov. 1988.
Zollinger et al., “Complex of Meningococcal Group B Polysaccharide and Type 2 Outer Membrane Protein Immunogenic in Man,”Journal of Clinical Investigation 63(5):836-848, May 1979.

Affiliated with

Also associated with

Rating

Proteosome influenza vaccine does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Proteosome influenza vaccine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Proteosome influenza vaccine will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2815197